Diabetes

Researchers discovered a statistically significant link between diabetes and all-cause mortality.

Top articles of the week from The American Journal of Pharmacy Benefits.

FDA-approved drug could reduce the risk of death in adults with diabetes and cardiovascular disease.

Top news of the day from across the health care landscape.

Jardiance could reduce the risk of death in adults with diabetes and cardiovascular disease.

Some conditions associated with type 2 diabetes may significantly impair renal function.

Top news of the day from across the health care landscape.

Inhibiting the SNAP23 protein could lead to increased insulin secretion.

Top news of the day from across the health care landscape.

Pharmacists can assist in patients’ blood glucose control, and provides the same benefit to that of other providers.

The FDA has approved Synjardy XR (empagliflozin and metformin hydrochloride, extended-release) tablets for the treatment of type 2 diabetes in adults. In combination with diet and exercise, Synjardy XR can improve blood sugar in patients.

The combination drug Synjardy XR approved for use in patients with type 2 diabetes.

The combination drug Synjardy XR approved for use in patients with type 2 diabetes.

Sitagliptin (Januvia/Merck) helps manage diabetes patients admitted hospital for general medical problems or surgery.

CVS Health has introduced Transform Diabetes Care, a new program available to help the company's pharmacy benefit management clients improve the health outcomes of their members, lower pharmacy costs through aggressive trend management, and decrease medical costs by improving medication adherence, A1C control and lifestyle management.

Pioglitazone may increase a patient’s risk of developing bladder cancer.

Pioglitazone may increase a patient’s risk of developing bladder cancer.

Modified kidney cells could potentially regulate insulin for 3 weeks in patients with diabetes.

A diet with foods rich in magnesium may reduce rates of cardiovascular disease, type 2 diabetes, and all-cause mortality.

Survey finds adults with type 2 diabetes were very willing to see their physicians and other medical professionals more often.

Study suggests link between diabetes and exposure to DDT, PCBs, and perfluoroalkyl.

Label expansion includes treatment of cardiovascular disease in adult patients with type 2 diabetes.

The FDA has approved a new indication for Boehringer Ingelheim’s empagliflozin (Jardiance), allowing it to be used to reduce the risk of cardiovascular death in adult patients with type 2 diabetes and cardiovascular disease.

A diagnostic diabetes breathalyzer may one day become a reality.

Phase 3 trials showed that empaglifloxin can reduce blood pressure in type 2 diabetes patients.

A hormone produced in the venom of the platypus and echidnas holds future potential to provide clues about treating diabetes, according to a study published in the Nature journal Scientific Reports.

The For Your Sweetheart campaign aims to improve education about the link between heart disease and diabetes.

A newly developed hand-held breath analyzer tests for elevated levels of acetone, which is strongly associated with undiagnosed diabetes.

The cost of providing essential medications may not be too costly in low- and middle-income countries.

Anti-vascular endothelial growth factor agents are the criterion standard for diabetic macular edema.